NCT06173349 2026-03-13
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
Phase 1 Recruiting
Clinical Trials
54 trialsNCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02817958 2025-06-26
MEGACEP
UNICANCER
Phase 2 Active not recruiting
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT06415318 2025-04-22
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT02305654 2025-04-02
InPACT
Institute of Cancer Research, United Kingdom
Phase 3 Recruiting
NCT03871036 2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00432094 2022-05-17
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00005028 2019-11-04
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT02109328 2019-04-11
Alisertib in Chemotherapy-pretreated Urothelial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00038246 2018-10-31
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00310011 2018-08-10
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
Wake Forest University Health Sciences
Phase 2 Completed
NCT00531687 2017-10-03
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
Rigshospitalet, Denmark
Phase 2 Terminated
NCT02911350 2017-10-02
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
NYU Langone Health
Phase 1 Completed
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT00183820 2017-07-07
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
University of Southern California
Phase 2 Completed
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01558492 2017-06-09
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00002931 2017-02-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00933426 2016-10-26
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00683059 2016-10-17
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003852 2016-06-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
UNICANCER
Phase 2 Terminated
NCT00002558 2016-05-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00423852 2016-05-18
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00002854 2015-08-26
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00933374 2015-03-18
RAD001
Heinrich-Heine University, Duesseldorf
Phase 2 Terminated
NCT00136175 2015-01-21
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00151034 2015-01-21
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00002949 2013-09-05
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
University of Chicago
Phase 1 Completed
NCT00084565 2013-07-10
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00002684 2013-07-03
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003105 2013-07-03
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00002559 2013-07-02
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00003133 2013-06-28
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00551122 2013-01-23
GemTIP
University of Southampton
Phase 1/2 Unknown
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT00005048 2012-11-09
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NYU Langone Health
Phase 1 Completed
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed